Cargando…

Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review

Background: The landscape of systemic therapies for advanced non-melanoma skin cancers has been revolutionized by the advent of immunotherapy. Cemiplimab is the only immune checkpoint inhibitor (ICI) approved by the European Medicine Agency for recurrent/metastatic cutaneous squamous cell carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banini, Marco, Salvestrini, Viola, Vultaggio, Alessandra, Perlato, Margherita, Mecheri, Valentina, Cerbai, Cecilia, Scotti, Vieri, Matucci, Andrea, Mangoni, Monica, Livi, Lorenzo, Bonomo, Pierluigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378378/ https://www.ncbi.nlm.nih.gov/pubmed/37504351 http://dx.doi.org/10.3390/curroncol30070491

Ejemplares similares

The impact of patient preference in the treatment algorithm for recurrent/metastatic head and neck squamous cell carcinoma
por: Salvestrini, Viola, et al.
Publicado: (2022)

The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

Baseline Eosinophil Count as a Potential Clinical Biomarker for Clinical Complexity in EGPA: A Real-Life Experience
por: Matucci, Andrea, et al.
Publicado: (2022)

EGPA Phenotyping: Not Only ANCA, but Also Eosinophils
por: Matucci, Andrea, et al.
Publicado: (2023)

How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies?
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside
por: Goodman, D.T.
Publicado: (2022)

Rapid response to cemiplimab for advanced cutaneous squamous cell carcinoma
por: Zargham, Hanieh, et al.
Publicado: (2022)

Mechanisms of Drug Desensitization: Not Only Mast Cells
por: Vultaggio, Alessandra, et al.
Publicado: (2020)

Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients
por: Van Meerhaeghe, T., et al.
Publicado: (2022)

Impact of COVID-19 on workload burden of a complex radiotherapy facility
por: Francolini, Giulio, et al.
Publicado: (2021)

Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis
por: Grace de Lima, Stacy, et al.
Publicado: (2023)

Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma
por: Marukian, Nareh Valerie, et al.
Publicado: (2020)

Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives
por: Mager, Layna, et al.
Publicado: (2023)

Efficacy of Cemiplimab in a Patient Affected by Cutaneous Squamous Cell Carcinoma and Myelodysplastic Syndrome
por: Proietti, Ilaria, et al.
Publicado: (2023)

Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion
por: Argenziano, Giuseppe, et al.
Publicado: (2022)

Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma
por: Paul, Eleanor, et al.
Publicado: (2021)

Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

Intravascular squamous cell carcinoma treated with cemiplimab
por: Rose, Alexander N., et al.
Publicado: (2021)

Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma
por: Virgen, Cesar A., et al.
Publicado: (2020)

Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios
por: Akhtar, Komal, et al.
Publicado: (2022)

Cemiplimab for cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer
Publicado: (2022)

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
por: Mallardo, Domenico, et al.
Publicado: (2023)

Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
por: Lai, Fei Ya, et al.
Publicado: (2023)

Cemiplimab-Induced Alopecia Areata
por: Piraccini, Bianca Maria, et al.
Publicado: (2023)

Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy
por: Ghetti, Gianni, et al.
Publicado: (2021)

Recurrent bilateral cutaneous squamous cell carcinoma arising within hypertrophic lichen planus with metastasis while on cemiplimab
por: Leeolou, Melissa C., et al.
Publicado: (2022)

Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: A case report
por: Bonomo, Pierluigi, et al.
Publicado: (2020)

Recent advances in de-intensification of radiotherapy in elderly cancer patients
por: Desideri, Isacco, et al.
Publicado: (2020)

Cemiplimab-Associated Sinusoidal Obstruction Syndrome
por: Sarsour, Nadeen Y., et al.
Publicado: (2023)

Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2021)

Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma—A Retrospective Single-Center Study
por: Kuzmanovszki, Daniella, et al.
Publicado: (2023)

Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center
por: Denaro, Nerina, et al.
Publicado: (2023)

Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719)
por: Francolini, Giulio, et al.
Publicado: (2022)

Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma
por: Buquicchio, Rosalba, et al.
Publicado: (2021)

Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group
por: Hober, Candice, et al.
Publicado: (2021)

Anti‐PD‐1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report
por: Alloghbi, Abdurahman, et al.
Publicado: (2021)

Addendum: Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2022)

Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer
por: Denis, Chloé, et al.
Publicado: (2021)

Self‐resolving bullous pemphigoid induced by cemiplimab
por: Molle, Mattia Fabio, et al.
Publicado: (2022)

Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Meattini, Icro, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_83rfcg2aqa2golnjqoujl5ptm5